The mRNA-1647 vaccine: A promising step toward the prevention of cytomegalovirus infection (CMV)
Cytomegalovirus (CMV) is a leading cause of congenital infections and significant health complications in immunocompromised individuals. With no licensed CMV vaccine available, the development of the mRNA-1647 offers promising advancements in CMV prevention. We have reviewed results from Phase 1 and...
Saved in:
Main Authors: | Adewunmi Akingbola, Abiodun Adegbesan, Olajumoke Adewole, Kolade Adegoke, Akpevwe Emmanuella Benson, Paul Ayomide Jombo, Sandra Uchechukwu Eboson, Victor Oluwasola, Ademola Aiyenuro |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2025-12-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2450045 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Incidence of ophthalmic manifestations in congenital cytomegalovirus (CMV)
by: Jennifer L. Rossen, et al.
Published: (2025-01-01) -
RfxCas13d-mediated inhibition of Circ1647 alleviates renal fibrosis via PI3K/AKT signaling pathway
by: Yufang Ni, et al.
Published: (2024-12-01) -
Dual bombard by Cytomegalovirus and Mycobacterium tuberculosis in a renal transplantee
by: Cinthujah Balachander, et al.
Published: (2024-01-01) -
Serological and Molecular Diagnosis of Human Cytomegalovirus among Hemodialysis Patients in Kirkuk/Iraq
by: Eman Ammar Ihsan, et al.
Published: (2024-10-01) -
Occurrence of Cytomegalovirus among pregnant antenatal women within Bauchi metropolis, Nigeria
by: Timothy Waje, et al.
Published: (2025-03-01)